CRIP1 and hepatocellular carcinoma: In HCC, CRIP1 interacts with gamma-butyrobetaine hydroxylase 1(BBOX1) and E3 ligase STIP1 homology and U-box containing protein 1 (STUB1) to promote BBOX1 ubiquitination and proteasome degradation, thereby reducing the acetylation of β-catenin, promoting its nuclear accumulation, and promoting the proliferation and differentiation of cancer cells, which is clinically associated with a worse prognosis [4].